코오롱생명과학
Financials
Valuation Metrics
코오롱생명과학's Market Cap is ₩2022B. At end of 2025 it was ₩6768B. Ranked #814 of 2,436 in KR market (top 33%), #372 of 1,649 on KOSDAQ (top 23%), #89 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 38%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 202.25B KRW | KR#814/2,436 Sec#89/234 |
| Revenue | 213.81B KRW | KR#979/2,436 Sec#53/234 |
| Net Income | 35.33B KRW | KR#461/2,436 Sec#30/234 |
| Total Assets | 1.15T KRW | KR#434/2,436 Sec#23/234 |
| Net Assets | 784.13B KRW | KR#341/2,436 Sec#22/234 |
| Employees | 444 | KR#549/2,436 Sec#44/234 |
| Value | ||
| P/E | 5.72x | KR#356/2,436 Sec#13/234 |
| P/B | 0.26x | KR#239/2,436 Sec#8/234 |
| PEG | 0.06x | KR#289/2,436 Sec#14/234 |
| P/S | 0.95x | KR#1,361/2,436 Sec#78/234 |
| EV/EBITDA | 20.15x | KR#1,017/2,436 Sec#58/234 |
| FCF Yield | -13.87% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | 4.51% | KR#1,059/2,436 Sec#79/234 |
| ROA | 3.08% | KR#945/2,436 Sec#82/234 |
| Op. Margin | 9.55% | KR#520/2,436 Sec#48/234 |
| Revenue Growth | 10.76% | KR#892/2,436 Sec#78/234 |
| Earnings Growth | 98.91% | KR#423/2,436 Sec#27/234 |
| Financial Health | ||
| Debt Ratio | 146.46% | KR#1,142/2,436 Sec#130/234 |
| Total Debt | 218.73B KRW | KR#464/2,436 Sec#22/234 |
| FCF | -28.05B KRW | KR#1,982/2,436 Sec#190/234 |
| Cash | 9.61B KRW | KR#1,692/2,436 Sec#135/234 |
| Current Ratio | 0.73x | KR#2,114/2,436 Sec#201/234 |
| Net Debt/EBITDA | 10.24x | KR#1,278/2,436 Sec#91/234 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -52.39% | KR#2,118/2,436 Sec#200/234 |
| 1M Return | -64.69% | KR#2,430/2,436 Sec#233/234 |
| From 52W High | -78.75% | KR#2,338/2,436 Sec#218/234 |
| 1Y MDD | -81.21% | KR#2,321/2,436 Sec#220/234 |
| Trading | ||
| Volume | 252,514 shares | KR#467/2,436 Sec#46/234 |
| Foreign Own. | 5.03% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 2,799 KRW | KR#298/2,436 Sec#19/234 |
| BPS | 59,900 KRW | KR#210/2,436 Sec#13/234 |
Company Info
Kolon Life Science, established in 2000 and listed on KOSDAQ in 2009, focuses on the production of active pharmaceutical ingredients (APIs), antimicrobial agents, and bio-new drug research and development. Its pharmaceutical business supplies APIs and pharmaceutical intermediates globally, and it markets the eco-friendly antimicrobial brand Cleanbio for use in anti-dandruff shampoos and paints. The company is dedicated to cell and gene new drug development, concentrating on research and development for neuropathic pain treatments and anticancer drugs. Kolon Life Science is headquartered in Gangseo-gu, Seoul Metropolitan City.